PTPatrick Treacy

Patrick Treacy

*This is an algorithmically generated author record based on publicly available information.

Patrick Treacy has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Treatment of scars resulting from combat wounds and burns: international consensus recommendations based on Ukrainian experience

    by O.YU. Turkevych, O.I. Blyshchuk–­iVanchuk, Ya.M. Turkevych, Hu. Cartier, D.O. Turkevych, T. T. Lotti, S.I. Derbak, O.M. Chemerys, P. Treacy, M.O. Turkevych

    This work was carried out in order to improve the methods of treatment of patients with post-traumatic and post-burn scars resulting from combat wounds and burns.The paper presents the clinical experience of doctors participating in the Ukrainian Charity project «Neopalymi» («Unburned») — subsidiary of NGO «Ukrainian Volunteer Center», with the support of the Ukrainian Association of Dermatovenerologists and Cosmetologists, in the treatment of patients with post-traumatic and post-burn scars, as well as analyzes the effectiveness of such treatment using generally accepted POSAS scale.As part of this study, protocol recommendations were developed for the treatment of patients with post-traumatic and post-burn scars resulting from combat wounds and burns. Based on the analysis of treatment results using the generally accepted POSAS scale, a fairly high clinical effectiveness of the proposed therapy has been proven.In fact, we can conclude that in the current dramatic times of the war in Ukraine, it was necessary to improve the methods of treating patients with scars that arose after combat wounds and burns. The proposed combination of laser and hardware procedures, as well as the use of injectables and, in particular, polynucleotides, botulinum toxin or polylactic acid, contributed to increasing the therapeutic effectiveness of the treatment of such patients, as well as achieving a more lasting aesthetic effect in them.

  • Top Cited Papers
    Open Access

    Hyaluronidase for Dermal Filler Complications: Review of Applications and Dosage Recommendations

    by George Kroumpouzos, Patrick Treacy

    Background: Hyaluronidase (Hyal) can reverse complications of hyaluronic acid (HA) fillers, which has contributed substantially to the popularity of such procedures. Still, there are differing opinions regarding Hyal treatment, including dosage recommendations in filler complication management. Objective: We aimed to address unanswered questions regarding Hyal treatment for HA filler complications, including timing and dosage, skin pretesting, properties of various Hyals and interactions with HA gels, and pitfalls of the treatment. Methods: PubMed and Google Scholar databases were searched from inception for articles on Hyal therapy for filler complications. Articles were evaluated regarding their contribution to the field. The extensive literature review includes international leaders’ suggestions and expert panels’ recommendations. Results: There are limited controlled data but increasing clinical experience with Hyal treatment. The currently used Hyals provide good results and have an acceptable safety profile. Nonemergent complications such as the Tyndall effect, noninflamed nodules, and allergic or hypersensitivity reactions should be treated with low or moderate Hyal doses. Hyal should be considered with prior or simultaneous oral antibiotic treatment in managing inflammatory nodules. Hyal may be tried for granulomas that have not responded to intralesional steroids. Emergent complications such as vascular occlusion and blindness require immediate, high-dose Hyal treatment. Regarding blindness, the injection technique, retrobulbar versus supraorbital, remains controversial. Ultrasound guidance can increase the efficacy of the above interventions. Conclusions: Hyal is essential in aesthetic practice because it can safely treat most HA filler complications. Immediate Hyal treatment is required for emergent complications. Aesthetic practitioners should be versed in using Hyal and effective dosage protocols.


  • Open Access

    Hyaluronidase for Dermal Filler Complications: Review of Applications and Dosage Recommendations (Preprint)

    by George Kroumpouzos, Patrick Treacy

    BACKGROUND Hyaluronidase (Hyal) can reverse complications of hyaluronic acid (HA) fillers, which has contributed substantially to the popularity of such procedures. Still, there are differing opinions regarding Hyal treatment, including dosage recommendations in filler complication management. OBJECTIVE We aimed to address unanswered questions regarding Hyal treatment for HA filler complications, including timing and dosage, skin pretesting, properties of various Hyals and interactions with HA gels, and pitfalls of the treatment. METHODS PubMed and Google Scholar databases were searched from inception for articles on Hyal therapy for filler complications. Articles were evaluated regarding their contribution to the field. The extensive literature review includes international leaders’ suggestions and expert panels’ recommendations. RESULTS There are limited controlled data but increasing clinical experience with Hyal treatment. The currently used Hyals provide good results and have an acceptable safety profile. Nonemergent complications such as the Tyndall effect, noninflamed nodules, and allergic or hypersensitivity reactions should be treated with low or moderate Hyal doses. Hyal should be considered with prior or simultaneous oral antibiotic treatment in managing inflammatory nodules. Hyal may be tried for granulomas that have not responded to intralesional steroids. Emergent complications such as vascular occlusion and blindness require immediate, high-dose Hyal treatment. Regarding blindness, the injection technique, retrobulbar versus supraorbital, remains controversial. Ultrasound guidance can increase the efficacy of the above interventions. CONCLUSIONS Hyal is essential in aesthetic practice because it can safely treat most HA filler complications. Immediate Hyal treatment is required for emergent complications. Aesthetic practitioners should be versed in using Hyal and effective dosage protocols. CLINICALTRIAL